-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$1.0072.41% Upside
Bolt Biotherapeutics, Inc. Frequently Asked Questions
-
What analysts cover Bolt Biotherapeutics, Inc.?
Bolt Biotherapeutics, Inc. has been rated by research analysts at Leerink Partners in the past 90 days.